Yossi Gross
Gründer bei TransPharma Medical Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Ilan Neugarten | M | 70 |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States.
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel.
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel.
Technion-Israel Institute of Technology
| 10 Jahre |
Gavriel David Meron | M | 71 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | 13 Jahre |
Sharon Goldfarb-Albak | F | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Etti Lavian | F | - |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 17 Jahre |
Amir Dagan | M | - |
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel. | 16 Jahre |
Hugo Vanerman | M | - |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | - |
Roy Katz | M | - |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 11 Jahre |
Tom Fleming | M | - |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | 6 Jahre |
Tal Simchony | M | 68 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | 15 Jahre |
Guy Ezekiel | M | 54 |
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel. | 11 Jahre |
Ben Tsai | M | 44 |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | - |
Paul van den Heuvel | M | - |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | - |
Jan Pensaert | M | 53 |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | - |
Yossi Rainbow Cohen | M | - |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 14 Jahre |
Tal Moyal | F | - |
Maxillent Ltd.
Maxillent Ltd. Medical SpecialtiesHealth Technology Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel. | - |
Galit Levin | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Boaz Brill | M | - |
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel. | - |
William Hawkins | M | 70 |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | 8 Jahre |
Francesco Maisano | M | - |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | - |
Annie Zanzuri | F | - |
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel. | - |
Zamir Halpern | M | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Alexander Rohlanko | M | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Adi Alphandary | M | - |
Maxillent Ltd.
Maxillent Ltd. Medical SpecialtiesHealth Technology Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel. | - |
David Mark Steinhaus | M | - |
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel. | - |
Gabriel Chaushu | M | - |
Maxillent Ltd.
Maxillent Ltd. Medical SpecialtiesHealth Technology Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel. | - |
William Tamborlane | M | - |
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel. | - |
Susan Lin | F | - |
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel. | - |
Jiawen Shen | M | - |
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel. | - |
Avi Sinay | M | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Jiang Zhang | M | - |
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel. | - |
Ruth Alon | F | 71 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Jason Martin | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Lawrence C. Best | M | 75 |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | - |
Zvi Limon | M | 65 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | 18 Jahre |
Larry Ellberger | M | 76 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Hadar Resnekov-Ron | M | 65 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Ronit Bendori | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Giora Arbel | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Judith Kornfeld | F | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Mario Thomas | M | 73 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Gadi Cohen | M | 68 |
Israel Aerospace Industries Ltd.
Israel Aerospace Industries Ltd. Aerospace & DefenseElectronic Technology Israel Aerospace Industries Ltd. engages in the development, sale, and maintenance of commercial and military aircrafts, missiles, and military electronic products. It operates through the following segments: Aviation, Military Aircraft, Missiles and Space Systems, and Elta Systems Ltd. The Aviation segment engages in the maintenance, renovation, and improvement of aircraft and aircraft engines, and conversion of passenger aircraft into cargo and refueling aircraft, and in the development and manufacture of aviation assemblies for military and commercial aircraft. The Military Aircraft segment engages in the development, manufacture, and sale of unmanned aircraft. The Missiles and Space Systems segment engages in the development, manufacture, and sale of attack and defense missile systems, satellites, and space assemblies. The Elta Systems Ltd segment engages in the military electronics field. The company was founded in 1953 and is headquartered in Lod, Israel. | 41 Jahre |
Joel P. Wyler | M | 74 |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | - |
Uriel Barkai | M | - |
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel. | - |
Paul A. Cornelison | M | 59 |
4Tech Cardio Ireland Ltd.
4Tech Cardio Ireland Ltd. Medical SpecialtiesHealth Technology 4Tech Cardio Ireland Ltd. develops and manufactures surgical devices. The company was founded in 2011 and is headquartered in Waltham, MA. | 8 Jahre |
Boris Kalandar | M | - |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 16 Jahre |
Zev Sohn | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Hana Gadassi | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Samuel Cubac | M | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Eitan Machover | M | 61 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Leon Recanati | M | 76 |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 17 Jahre |
Yael Kenan | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Ronit Nahary | F | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Shimon Weintraub | M | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Hadar Better | M | - |
Maxillent Ltd.
Maxillent Ltd. Medical SpecialtiesHealth Technology Maxillent Ltd. develops and manufactures dental implants. Its products include iraise, isure, prosthetics, surgical instruments and bone graft materials. The company was founded in 2008 and is headquartered in Herzliya, Israel. | - |
Erez Adunsky | M | - |
Enopace Biomedical Ltd.
Enopace Biomedical Ltd. Medical SpecialtiesHealth Technology Enopace Biomedical Ltd. develops medical devices to treat heart failure patients. The firm's technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload and improves the systolic/diastolic ratio. The company was by Yossi Gross and Amir Dagan in 2008 and is headquartered in Caesarea, Israel. | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Efi Cohen-Arazi | M | 51 |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 12 Jahre |
Benad Goldwasser | M | 73 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Gustavo Auerbach | M | - |
E-Pill Pharma Ltd.
E-Pill Pharma Ltd. Medical SpecialtiesHealth Technology E-Pill Pharma Ltd. develops oral drug delivery platform. Its drug delivery platform is used to administer peptides, molecule and low bioavailability drugs, such as insulin, growth hormone, LMW Heparin, PTH, and interferon. The company was founded in 2003 by Yossi Gross and Yoram Sela and is headquartered in Caesarea, Israel. | - |
Shirley Giorini-Silfen | M | - |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 12 Jahre |
Tehila Hyman | M | - |
GluSense Ltd.
GluSense Ltd. Electronic Equipment/InstrumentsElectronic Technology GluSense Ltd. develops technology for Continuous Glucose Monitoring. The firm develops a miniature, Long-Term, Implantable Continuous Glucose Monitoring (CGM) system for diabetes patients, this system includes a miniature sensor implanted under the skin and an external wearable unit, e.g. a watch. Its wearable unit reads the signal from the implant and provides basic display and alarms. The company was founded by Yossi Gross in 2007 and is headquartered in Rehovot, Israel. | - |
Yoram Sela | M | - |
E-Pill Pharma Ltd.
E-Pill Pharma Ltd. Medical SpecialtiesHealth Technology E-Pill Pharma Ltd. develops oral drug delivery platform. Its drug delivery platform is used to administer peptides, molecule and low bioavailability drugs, such as insulin, growth hormone, LMW Heparin, PTH, and interferon. The company was founded in 2003 by Yossi Gross and Yoram Sela and is headquartered in Caesarea, Israel. | 9 Jahre |
Ziv Belsky | M | 55 |
E-Pill Pharma Ltd.
E-Pill Pharma Ltd. Medical SpecialtiesHealth Technology E-Pill Pharma Ltd. develops oral drug delivery platform. Its drug delivery platform is used to administer peptides, molecule and low bioavailability drugs, such as insulin, growth hormone, LMW Heparin, PTH, and interferon. The company was founded in 2003 by Yossi Gross and Yoram Sela and is headquartered in Caesarea, Israel. | 5 Jahre |
Zohar Avrahami | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Oz Cabiri | M | - |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Mony Rueven | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Itzhak H. Maor | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Yehoshua Eldar | M | - |
Israel Aerospace Industries Ltd.
Israel Aerospace Industries Ltd. Aerospace & DefenseElectronic Technology Israel Aerospace Industries Ltd. engages in the development, sale, and maintenance of commercial and military aircrafts, missiles, and military electronic products. It operates through the following segments: Aviation, Military Aircraft, Missiles and Space Systems, and Elta Systems Ltd. The Aviation segment engages in the maintenance, renovation, and improvement of aircraft and aircraft engines, and conversion of passenger aircraft into cargo and refueling aircraft, and in the development and manufacture of aviation assemblies for military and commercial aircraft. The Military Aircraft segment engages in the development, manufacture, and sale of unmanned aircraft. The Missiles and Space Systems segment engages in the development, manufacture, and sale of attack and defense missile systems, satellites, and space assemblies. The Elta Systems Ltd segment engages in the military electronics field. The company was founded in 1953 and is headquartered in Lod, Israel. | - |
Shachar Peretz | M | 71 |
Technion-Israel Institute of Technology
| 4 Jahre |
Itzchak Amitay | M | 73 |
Technion-Israel Institute of Technology
| 4 Jahre |
Meir Arnon | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Simcha Gochman | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Morti Tenenhaus | M | 69 |
Technion-Israel Institute of Technology
| 3 Jahre |
Amos Anatot | M | 71 |
Technion-Israel Institute of Technology
| 4 Jahre |
Nissim Benoz | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Uri Shetrit | M | 72 |
Technion-Israel Institute of Technology
| 4 Jahre |
Nitzan Sapir | M | 67 |
Technion-Israel Institute of Technology
| 4 Jahre |
Shlomo Liran | M | 73 |
Technion-Israel Institute of Technology
| 4 Jahre |
Elenora Yoeli | F | - |
Technion-Israel Institute of Technology
| 1 Jahre |
Aaron Choresh | M | 78 |
Technion-Israel Institute of Technology
| 4 Jahre |
Ehud Shoshani | M | - |
Technion-Israel Institute of Technology
| 3 Jahre |
Zeev Vurembrand | M | 73 |
Technion-Israel Institute of Technology
| 4 Jahre |
Arie Silverberg | M | 77 |
Technion-Israel Institute of Technology
| 1 Jahre |
Israel Cidon | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Zvi Or-Bach | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
David Mahlab | M | 67 |
Technion-Israel Institute of Technology
| 4 Jahre |
Ari Sonesh | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Shlomo Weitz | M | - |
Technion-Israel Institute of Technology
| 4 Jahre |
Zvi Schechter | M | 71 |
Technion-Israel Institute of Technology
| 3 Jahre |
Moshe Yanai | M | 75 |
Technion-Israel Institute of Technology
| 4 Jahre |
Eli Doron | M | 71 |
Israel Aerospace Industries Ltd.
Israel Aerospace Industries Ltd. Aerospace & DefenseElectronic Technology Israel Aerospace Industries Ltd. engages in the development, sale, and maintenance of commercial and military aircrafts, missiles, and military electronic products. It operates through the following segments: Aviation, Military Aircraft, Missiles and Space Systems, and Elta Systems Ltd. The Aviation segment engages in the maintenance, renovation, and improvement of aircraft and aircraft engines, and conversion of passenger aircraft into cargo and refueling aircraft, and in the development and manufacture of aviation assemblies for military and commercial aircraft. The Military Aircraft segment engages in the development, manufacture, and sale of unmanned aircraft. The Missiles and Space Systems segment engages in the development, manufacture, and sale of attack and defense missile systems, satellites, and space assemblies. The Elta Systems Ltd segment engages in the military electronics field. The company was founded in 1953 and is headquartered in Lod, Israel. | - |
Zvi Krieger | M | 68 |
Technion-Israel Institute of Technology
| 4 Jahre |
Avery More | M | 69 |
Technion-Israel Institute of Technology
| 4 Jahre |
Aviu Ben-Horrin | M | 75 |
Technion-Israel Institute of Technology
| 4 Jahre |
Shula Recanati | M | - |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 13 Jahre |
Ziv Kop | M | 53 |
Rainbow Medical Ltd.
Rainbow Medical Ltd. Investment ManagersFinance Rainbow Medical Ltd. (Rainbow Medical) is a venture capital firm founded in 2007 by Efi Cohen Arazi and Yossi Gross. The firm is headquartered in HaMerkaz, Israel with an additional offices in China and United States. | 6 Jahre |
Ittai Harel | M | 56 |
E-Pill Pharma Ltd.
E-Pill Pharma Ltd. Medical SpecialtiesHealth Technology E-Pill Pharma Ltd. develops oral drug delivery platform. Its drug delivery platform is used to administer peptides, molecule and low bioavailability drugs, such as insulin, growth hormone, LMW Heparin, PTH, and interferon. The company was founded in 2003 by Yossi Gross and Yoram Sela and is headquartered in Caesarea, Israel. | - |
Yaron Sheinman | M | 69 |
Israel Aerospace Industries Ltd.
Israel Aerospace Industries Ltd. Aerospace & DefenseElectronic Technology Israel Aerospace Industries Ltd. engages in the development, sale, and maintenance of commercial and military aircrafts, missiles, and military electronic products. It operates through the following segments: Aviation, Military Aircraft, Missiles and Space Systems, and Elta Systems Ltd. The Aviation segment engages in the maintenance, renovation, and improvement of aircraft and aircraft engines, and conversion of passenger aircraft into cargo and refueling aircraft, and in the development and manufacture of aviation assemblies for military and commercial aircraft. The Military Aircraft segment engages in the development, manufacture, and sale of unmanned aircraft. The Missiles and Space Systems segment engages in the development, manufacture, and sale of attack and defense missile systems, satellites, and space assemblies. The Elta Systems Ltd segment engages in the military electronics field. The company was founded in 1953 and is headquartered in Lod, Israel. | 2 Jahre |
Meron Mann | M | 72 |
G.I. View Ltd.
G.I. View Ltd. Medical SpecialtiesHealth Technology G.I. View Ltd. develops endoscopy products for gastrointestinal applications. It offers edge endoscopes for the gastrointestinal market that set its products. The company was founded by Benad Goldwasser, Oz Cabiri and Yossi Gross in 2003 and is headquartered in Ramat Gan, Israel. | - |
Meir Warshavsky | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Marina Konorty | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Israel | 91 | 91,00% |
Irland | 9 | 9,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Yossi Gross
- Persönliches Netzwerk